PTPRC and acute myeloid leukemia: The drug-treated group received a combination of FLT3 inhibitor AC220 (20 mg/kg, orally), antiinflammatory compound APX 3330 (50 mg/kg, orally), and DNMT methylation inhibitor decitabine (1 mg/kg, i.p.)as showed in the experimental design presented in Figure 7A. As shown in Figure 7B, a combination drug treatment significantly inhibited the PB engraftment of human AML CD45+ cells over an 18-day period (red versus blue line).